Macquarie Group LTD Reata Pharmaceuticals Inc Transaction History

Macquarie Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$19.41 - $36.49 $24,495 - $46,050	-1,262 Reduced 45.59%	1,506 $70,000
Q2 2022 Aug 15, 2022	BUY	$20.71 - $36.5 $19,384 - $34,164	936 Added 51.09%	2,768 $84,000
Q4 2021 Feb 11, 2022	BUY	$25.61 - $110.96 $31,705 - $137,368	1,238 Added 208.42%	1,832 $48,000
Q3 2021 Nov 12, 2021	BUY	$100.0 - $143.02 $22,300 - $31,893	223 Added 60.11%	594 $60,000
Q2 2021 Aug 13, 2021	SELL	$78.27 - $151.29 $28,177 - $54,464	-360 Reduced 49.25%	371 $53,000
Q1 2021 May 14, 2021	SELL	$94.25 - $132.81 $20,735 - $29,218	-220 Reduced 23.13%	731 $73,000
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $21,324 - $38,585	-209 Reduced 18.02%	951 $118,000
Q3 2020 Nov 13, 2020	SELL	$93.53 - $163.34 $709,892 - $1.24 Million	-7,590 Reduced 86.74%	1,160 $113,000
Q2 2020 Aug 11, 2020	SELL	$126.3 - $176.56 $380,289 - $531,622	-3,011 Reduced 25.6%	8,750 $1.37 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $877,017 - $2.56 Million	11,761 New	11,761 $2.41 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.